LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Dry AMD is a leading cause of permanent vision loss in people over the age of 50. GT005 is a one-time AAV-based gene therapy that is delivered under the retina. The goal of the Phase II clinical trial programme is to determine if GT005 has the potential to slow the progression of GA.
Gyroscope plans to conduct two Phase II trials evaluating GT005 in people with GA. The first, called EXPLORE, is enrolling people who have a mutation in their Complement Factor I (CFI) gene [NCT04437368]. The first patient to receive GT005 in EXPLORE was enrolled and dosed by Dr. Arshad M. Khanani at Sierra Eye Associates in Reno, Nev., USA.
Geographic atrophy is a devastating diagnosis, as there are no approved treatments for this gradual and irreversible loss of vision, said Arshad M. Khanani, M.D., M.A., Director of Clinical Research at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine, and an investigator in the EXPLORE trial. We are excited to participate in this trial evaluating GT005 for the potential to slow progression of geographic atrophy. We believe one-time gene therapies could be a major advancement in the field of retinal disease.
GT005 is designed to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. An overactive complement system has been implicated in the development of AMD. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production will dampen the systems overactivity and reduce inflammation, with the goal of preserving a persons eyesight.
Research has found that approximately 3% of people with dry AMD have certain CFI mutations that correlate with low CFI levels in the blood and a higher risk of developing AMD.1 Gyroscope estimates that more than 100,000 people with GA in the United States and EU5 European countries may have these mutations.1,2,3,4 The EXPLORE trial will evaluate GT005 in this group of people with mutations in their CFI gene.
Research has also shown that a small supplementation of CFI can normalise complement activity in the blood,5 suggesting GT005 may also be applicable for a broader group of people with GA. It is estimated that approximately one million people in the United States alone have GA.4 Gyroscope therefore plans to initiate a second Phase II trial in 2020 that will evaluate GT005 in a broader GA population.
We are excited about the potential of GT005 for people with dry AMD. Research suggests GT005 may be best suited for people with certain mutations in their CFI gene. However, evidence also suggests it may have potential for a broader population of people with geographic atrophy, said Nadia Waheed, M.D., MPH, Chief Medical Officer of Gyroscope. We have designed our clinical programme to evaluate these groups in two distinct Phase II trials, with the goal of determining which patients GT005 may be most appropriate for and to further our understanding of the role of the complement system in AMD.
About the EXPLORE Trial
EXPLORE is a Phase II, multicentre, randomised trial evaluating the safety and efficacy of GT005 administered as a single subretinal injection.
EXPLORE is enrolling people who are aged 55 or older and have a clinical diagnosis of GA secondary to dry AMD and who have a mutation of the CFI gene. People being screened for the trial will be genotyped for the mutations. Trial participants will be randomised to one of three treatment arms: GT005 dose 1, GT005 dose 2 or a control arm. Participants in the control arm will receive current standard of care. The primary endpoint of EXPLORE is progression of GA over 48 weeks. The study will also evaluate GT005 for various safety and tolerability measures. Gyroscope plans to enroll approximately 75 patients at approximately 40 centres based in the United States, United Kingdom, Europe and Australia.
Gyroscope will announce details about the second Phase II trial of GT005 at a later date.
About Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA)
AMD is a leading cause of blindness affecting an estimated 196 million people globally.6 AMD typically affects people aged 50 and older, and causes a gradual and permanent loss of central vision that worsens over time.7 There are no approved treatments for the dry form of AMD, which is the most common, impacting approximately 90% of people with the disease.8 As dry AMD advances it leads to GA, an irreversible degeneration of retinal cells. This vision loss can be devastating, severely impacting a persons daily life as they lose the ability to drive, read and even see the faces of loved ones.
About Gyroscope Therapeutics: Vision for Life
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing and delivering gene therapy beyond rare disease to treat a leading cause of blindness, dry AMD. Our lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and a Phase II clinical trial called EXPLORE.
Syncona Ltd, our lead investor, helped us create the only retinal gene therapy company to combine discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. For more information visit: http://www.gyroscopetx.com and follow us on Twitter (@GyroscopeTx) and on LinkedIn.
References
1 Kavanagh D, Yu Y, Schramm EC, et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet. 2015;24(13):3861-3870.2 Data on File.3 Friedman DS, O'Colmain BJ, Muoz B, et al. Prevalence of age-related macular degeneration in the United States [published correction appears in Arch Ophthalmol. 2011 Sep;129(9):1188]. Arch Ophthalmol. 2004;122(4):564-572.4 Rudnicka AR, Kapetanakis VV et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol 2015;160:85-93.5 Lachmann PJ, Lay E, Seilly DJ, Buchberger A, Schwaeble W, Khadake J. Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype. Clin Exp Immunol. 2016;183(1):150-156.6 Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106116.7 National Eye Institute. Age-Related Macular Degeneration. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration. Accessed July 16, 2020.8 Centers for Disease Control and Prevention. Age-Related Macular Degeneration. https://www.cdc.gov/visionhealth/basics/ced/. Page last reviewed June 3, 2020. Accessed August 4, 2020.
Follow this link:
Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular...
- Could my glasses be making my eyesight worse? - The Conversation - April 8th, 2024
- Eyeglasses Improve Income as Well as Sight, Study Shows - The New York Times - April 8th, 2024
- John Berger Lost His Eyesight to Cataracts and Learned to See - Hyperallergic - April 8th, 2024
- Eye Health Facts: What You Need to Know About the Eyes - Prevention Magazine - April 8th, 2024
- Reading glasses are good for your eyes and your income : Goats and Soda - NPR - April 8th, 2024
- 'The sight to fight:' Yorktown military members make thousands of glasses for the service - News 3 WTKR Norfolk - April 8th, 2024
- How to Watch the Solar Eclipse Without Damaging Your Eyes - Verywell Health - April 8th, 2024
- Protect Your Eyes While Watching the Solar EclipseExpert Advice from NYU Langone's Dr. Nitish Mehta - NYU Langone Health - April 8th, 2024
- 10 Daily Habits That Will Help You Protect Your Eye Health - CNET - January 25th, 2024
- Undergoing cataract surgery when it's not necessary? Some do it to improve their eyesight, but it's not without risk - The Conversation Indonesia - January 25th, 2024
- Sight Care Reviews - Is It Safe to Use? The Most Important Fact to Know Before Buy! - Kent Reporter - January 25th, 2024
- Apple has big and cartoonish plans for Vision Pro's EyeSight - AppleInsider - January 25th, 2024
- National Center for Children's Vision and Eye Health at Prevent Blindness Celebrates 15th Anniversary in 2024 - PR Web - January 25th, 2024
- Understanding Computer Vision Syndrome: Causes, Symptoms, and Practical Solutions - Medriva - January 25th, 2024
- 8 Eye Issues You Should Never Ignore - Right as Rain by UW Medicine - January 9th, 2024
- Digital eye strain is a growing issue as the muscles of the eyes work overtime, warn vision experts - Fox News - January 9th, 2024
- Know the Facts About Glaucoma - MedicineNet - January 9th, 2024
- New Year, New Vision: Top Resolutions For Optimal Eye Health - ABP Live - January 9th, 2024
- Childhood Myopia and Its Impact on Vision Loss: What Causes It? - News18 - January 9th, 2024
- What you see first in optical illusion can reveal a lot about you but youll need 20/20 vision to spot hi... - The Sun - January 9th, 2024
- The Importance of Eye Care: Preventing Vision Impairments and Maintaining Good Eye Health - Medriva - December 30th, 2023
- Six ways to look after your eyes in 2024 - The Conversation - December 30th, 2023
- 6 Essential Ways to Safeguard and Improve Your Vision in 2024 - Medriva - December 30th, 2023
- SightCare Reviews - Obvious Hoax or Safe Pills That Work? Fake Scams to Avoid | Courier-Herald - Enumclaw Courier-Herald - December 30th, 2023
- SightCare Reviews - Honest Customer Warning! Real Eyesight Support or Fake Hype? - Bothell-Kenmore Reporter - December 30th, 2023
- Global Intraocular Lens Market Surges with Innovations in Vision Correction | CAGR of 5.6% - PharmiWeb.com - December 30th, 2023
- Infection of the eye, and how to protect vision - The Hindu - December 30th, 2023
- Optical Illusion Eye Test: Can you find the dog in the street in 7 seconds? - Jagran Josh - December 30th, 2023
- You have 20/20 vision if you can find the hidden chick amongst these ducks - IndiaTimes - December 30th, 2023
- Eye Doc: Look *Here* While You Drive + 8 More Genius Tips to Improve Night Vision Behind The Wheel - Yahoo Life - December 22nd, 2023
- Designer creates inclusive clothing company after losing eyesight - Fox Business - December 22nd, 2023
- What is the state of American eyesight? - USAFacts - December 22nd, 2023
- When temporary vision loss in one eye isn't a sign of stroke - Harvard Health - December 22nd, 2023
- 10 Hacks That Can Naturally Boost Your Eye Health Today - CNET - December 22nd, 2023
- SightCare Reviews (Critical Customer Warning!) Know The Sight Care Facts Before Buy - Ukiah Daily Journal - December 22nd, 2023
- Everyone can spot the building with the hole in it but only those with 20/20 vision can find the giant C... - The US Sun - December 22nd, 2023
- Flashes, shimmers and blind spots: Here's what migraine aura looks like - The Washington Post - December 22nd, 2023
- Doctors Reveal the Snack That Cuts Your Risk of Vision-Clouding Cataracts in Half - Yahoo Life - December 22nd, 2023
- Yoga For Healthy Vision: 5 Extraordinary Yogasanas To Improve Eyesight - Netmeds.com - December 22nd, 2023
- Everyone can spot the teddy bears but you have 20/20 vision if you can see the bee in the bedroom in under... - The US Sun - December 22nd, 2023
- Reindeers blue eyes act as night vision goggles to help them find food in winter - The Guardian - December 22nd, 2023
- 6 Bad Habits That Could Be Damaging Your Eyesight - Money Talks News - December 22nd, 2023
- Reindeer vision may have evolved to spot favorite food in the snowy dark of winter - Phys.org - December 22nd, 2023
- Human eyes: How they work, and their amazing anatomy - BBC Science Focus Magazine - December 22nd, 2023
- Why reindeer eyes shine blue in the winter - The Washington Post - December 22nd, 2023
- Can Everyone Unfocus Their Eyes On Command? - IFLScience - December 22nd, 2023
- You have the eyes of a hunter if you can spot the dogs owner in the picture in 8 seconds! - Jagran Josh - December 22nd, 2023
- Everyone can see the Christmas trees but you could have 20/20 vision if you can spot the star hiding in t... - The US Sun - December 22nd, 2023
- Here's how eye exams can reveal several health conditions beyond your sight - The Record (New Westminster) - December 22nd, 2023
- At Bread for the Citys vision clinic, patients can see clearly now - The Washington Post - December 13th, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or Scam (2024) | Vashon-Maury Island Beachcomber - Vashon-Maury Island Beachcomber - December 13th, 2023
- The Benefits of Donning Prescription Sunglasses for Vision Correction and Protection - Anti Aging News - December 13th, 2023
- Vision Pro training of Apple retail store employees to start soon - BGR - December 13th, 2023
- 6 Best Vitamins and Supplements for Healthy Eyes - CNET - December 13th, 2023
- Eye Health: How to Protect Eyes From Digital Strain, Vision Loss and More? 5 Tips - India.com - December 13th, 2023
- How to watch the solar eclipse without damaging your eyesight - WATE 6 On Your Side - October 16th, 2023
- Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight - Times Now - May 17th, 2023
- Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones - April 15th, 2023
- Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference - April 15th, 2023
- GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update - April 15th, 2023
- Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow - April 15th, 2023
- Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting - April 15th, 2023
- Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference - April 15th, 2023
- Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023 - April 15th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15th, 2023
- Alvotech Provides Regulatory Update on AVT02 Biologics License Application - April 15th, 2023
- Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 - April 15th, 2023
- Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China - April 15th, 2023
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting - April 15th, 2023
- QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023 - April 15th, 2023
- ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein - April 15th, 2023
- International Carrot Day: From healthy eyesight to weight loss - 5 wonderful benefits of carrot - Zee Business - April 7th, 2023
- How the Human Eye Works | Cornea Layers/Role | Light Rays - NKCF.org - December 11th, 2022
- Eye Emergencies: Types, Symptoms, and Prevention - Healthline - November 25th, 2022
- The criteria for certification | RNIB - November 25th, 2022
- Foresight: Eye-Net Successfully Showcases its Advanced Solution to Leading OEMs and Tier One Suppliers in Japan - Marketscreener.com - November 25th, 2022
- Can you see me now? Average person begins worrying about their vision at age 39 - Study Finds - September 29th, 2022
- Contact lens wearers at higher risk of rare eye infection are you caring for your lenses the right way? - News24 - September 29th, 2022
- A man who popped a champagne cork into his eye says it felt like being poked 'times a thousand.' His vision was saved after months of treatment but it... - September 29th, 2022